Drug Type Small molecule drug |
Synonyms + [1] |
Target |
Action inhibitors |
Mechanism MLL1 inhibitors(lysine methyltransferase 2A inhibitors), menin inhibitors(Menin inhibitors) |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
Molecular FormulaC27H29F3N6O3S |
InChIKeyFFHYBSANKGPTCW-VOQZNFBZSA-N |
CAS Registry2440018-29-9 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Acute lymphoblastic leukemia recurrent | Phase 2 | United States | 25 Mar 2021 | |
Chronic Myelomonocytic Leukemia | Phase 2 | United States | 25 Mar 2021 | |
Lymphoma | Phase 2 | United States | 25 Mar 2021 | |
Lymphoma | Phase 2 | United States | 25 Mar 2021 | |
Recurrent Myelodysplastic Syndrome | Phase 2 | United States | 25 Mar 2021 | |
Refractory acute myeloid leukemia | Phase 2 | United States | 25 Mar 2021 | |
Refractory Adult Acute Lymphoblastic Leukemia | Phase 2 | United States | 25 Mar 2021 | |
refractory chronic myelocytic leukemia | Phase 2 | United States | 25 Mar 2021 | |
Refractory Myelodysplastic Syndrome | Phase 2 | United States | 25 Mar 2021 | |
Relapsing acute myeloid leukemia | Phase 2 | United States | 25 Mar 2021 |